Quest Diagnostics Stock (NYSE:DGX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$151.52

52W Range

$123.04 - $165.32

50D Avg

$156.62

200D Avg

$145.68

Market Cap

$17.09B

Avg Vol (3M)

$830.48K

Beta

0.89

Div Yield

$2.96 (1.93%)

DGX Company Profile


Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

50,000

IPO Date

Dec 17, 1996

Website

DGX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Other Segments$276.00M$274.00M-
Diagnostic Information Services Business$8.98B$9.61B-
Routine clinical testing services--$4.29B
Anatomic pathology testing services--$553.00M
COVID-19 Testing Services--$2.77B
Gene-based and esoteric testing services--$2.88B
All other services--$294.00M

Fiscal year ends in Dec 23 | Currency in USD

DGX Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.25B$9.88B$10.79B
Operating Income$1.26B$1.43B$2.38B
Net Income$854.00M$942.00M$2.00B
EBITDA$1.26B$1.81B$3.16B
Basic EPS$7.63$8.10$15.85
Diluted EPS$7.56$7.97$15.55

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 22, 24 | 11:40 AM
Q2 24Jul 23, 24 | 12:12 PM
Q1 24Apr 23, 24 | 12:31 PM

Peer Comparison


TickerCompany
ICLRICON Public Limited Company
TWSTTwist Bioscience Corporation
RVTYRevvity, Inc.
MTDMettler-Toledo International Inc.
IQVIQVIA Holdings Inc.
IDXXIDEXX Laboratories, Inc.
AAgilent Technologies, Inc.
CRLCharles River Laboratories International, Inc.
WATWaters Corporation
SHCSotera Health Company